Organon & Co. (OGN)
NYQ – Real Time Price. Currency in USD
13.31
-0.02 (-0.15%)
At close: May 12, 2026, 4:00 PM EDT
Find any stock by ticker or company name

NYQ – Real Time Price. Currency in USD
13.31
-0.02 (-0.15%)
At close: May 12, 2026, 4:00 PM EDT
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women’s health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products to control and prevent asthma symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.
| Name | Position |
|---|---|
| Dr. Juan Camilo Arjona Ferreira M.D. | Executive VP, Head of Research & Development and Chief Medical Officer |
| Mr. Aaron Falcione | Executive VP & Chief Human Resources Officer |
| Mr. Daniel Karp | Chief Strategy Officer & Head of Corporate Development |
| Mr. Joseph T. Morrissey Jr. | Chief Executive Officer |
| Mr. Kirke Weaver | Executive VP, General Counsel & Corporate Secretary |
| Mr. Matthew M. Walsh C.F.A. | Executive VP & CFO |
| Mr. Vittorio Nisita | Executive VP and Head of Enterprise Services & Solutions |
| Ms. Carrie Smith Cox | Executive Chair of the Board |
| Ms. Jennifer Halchak | Head of Investor Relations |
| Ms. Rachel A. Stahler | Executive VP, Chief Information Officer and Chief Digital & Growth Officer |
| Date | Type | Document |
|---|---|---|
| 2026-05-04 | 10-Q | ogn-20260331.htm |
| 2026-04-30 | 8-K | tm2613165d1_8k.htm |
| 2026-04-27 | DEFA14A | d29178ddefa14a.htm |
| 2026-04-27 | 8-K | d38652d8k.htm |
| 2026-04-24 | DEFA14A | defa_14a_fy2025.htm |
| 2026-04-24 | DEF 14A | ogn-ogn_proxy_2026_html_only.pdf |
| 2026-02-24 | 10-K | ogn-20251231.htm |
| 2026-02-20 | 8-K | tm266880d1_8k.htm |
| 2026-02-12 | 8-K | tm266144d1_8k.htm |
| 2025-11-10 | 10-K/A | ogn-20241231x10ka.htm |